MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer

被引：0

作者：

Yan, D. ^{[1
]}

Huelse, J. ^{[1
]}

Parker, R. ^{[1
]}

Wang, X. ^{[2
,3
]}

Frye, S. ^{[3
,4
,5
]}

Earp, H. S. ^{[5
,6
]}

Deryckere, D. ^{[1
]}

Graham, D. ^{[1
]}

机构：

[1] Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Pediat, Atlanta, GA USA

[2] Ctr Integrat Chem Biol & Drug Discovery, Chem Biol & Med Chem, Chapel Hill, NC USA

[3] Div Chem Biol, Chapel Hill, NC USA

[4] Ctr Integrat Chem Biol & Drug Discovery, Chapel Hill, NC USA

[5] UNC Lineberger Comprehens Canc Ctr, Med, Chapel Hill, NC USA

[6] Sch Med, Pharmacol, Chapel Hill, NC USA

来源：

关键词：

Non-small cell lung cancer; EGFR mutation; osimertinib; resistance; MERTK;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.18

引用

页码：S1147 / S1147

页数：1